USD10
ALLO Shares
About Allogene TherapeuticsAllogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
USD10
ALLO Shares
About Allogene TherapeuticsAllogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Stats
TRADING WINDOW
Open
CLOSES AT
8:00 PM GMT+0
MARKET CAP
$564.57M
OPEN PRICE
$2.14
LOW (1Y)
$0.8621
HIGH (1Y)
$2.80
LOW (24H)
$2.13
HIGH (24H)
$2.53
VOLUME (24H)
$5.86M
75.23%
Price history
Time | Price | Change |
|---|---|---|
Today | $2.14 | |
1 Day | $2.14 | |
1 Week | $2.46 | |
1 Month | $2.04 | |
1 Year | $1.68 |